RBC Capital raised the firm’s price target on Ligand (LGND) to $155 from $143 and keeps an Outperform rating on the shares. The firm cites the company’s better than expected Q4 results while the management reaffirmed 2025 revenue and core EPS guidance and anticipates multiple value-creating milestones in 2025, including a potential strategic transaction and subsequent launch of Zelsuvmi by mid-2025, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND: